Whitehawk Therapeutics, акция обыкновенная (US00032Q1040, WHWK, 335, 3350, WHWK.P)

Whitehawk Therapeutics, Inc. is a developer of albumin-bound drugs designed to realize the full potential of mTOR inhibition by highly efficient target suppression in mTOR-driven diseases and biomarker-driven patient populations. The company is engaged in developing drugs that help in high tumour penetration due to mechanisms of albumin uptake in tumours and other areas with tissue remodelling or inflammation, enabling patients to block the activity of a protein called mTOR, which is known to be overactive in PEComa cancer cells.

• Выручка
• Чистая прибыль
• EBITDA
• Активы
• Капитал
• Рентабельность по EBITDA (%)
• Чистый долг / EBITDA
• Общий долг / Капитал